In a parallel‐design RCT, 72‐hour infusion of GLP‐1 did not reduce intravenous insulin requirement nor the rate of hypoglycaemia compared with saline control, although there was less plasma glucose variability with GLP‐1. The gene discussed is INS; the disease is Hypoglycemia.